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We have cloned and sequenced a cDNA (RPR4) encoding a new member of the secretin/calcitonin/parathyroid hormone (PTH) receptor family. 
RPR4 was identified by PCR of rat pituitary cDNA, and a full-length clone was isolated from a rat olfactory bulb cDNA library. When RPR4 
was functionally expressed in COS 7 cells, cyclic adenosine monophosphate (cAMP) production was stimulated by vasoactive intestinal peptide 
(VIP), pituitary adenylate cyclase activating peptides (PACAP-38 and PACAP-27) and helodermin, with equal potency. Peptide histidine isoleucine 
(PHI) and rat growth ormone releasing hormone (rGHRH) also stimulated cAMP production at lower potency. This suggests that RPR4 encodes 
a novel VIP receptor which we have designated the VIP 2 receptor. In situ hybridisation showed that mRNA for this receptor was present mainly 
in the thalamus, hippocampus and in the suprachiasmatic nucleus. 
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1. INTRODUCTION 
Vasoactive intestinal peptide (VIP) is an amidated 28 
amino acid peptide which belongs to a family of regula- 
tory peptides including secretin, glucagon and growth 
hormone-releasing hormone (GHRH). It functions as a 
neuroendocrine hormone and neurotransmitter, acti- 
vating adenylate cyclase [1,2] through a G protein-cou- 
pled receptor [3]. VIP has a number of actions in the 
periphery, including vasodilatation, stimulation of elec- 
trolyte secretion and smooth muscle relaxation [4]. The 
presence of specific VIP binding sites in defined path- 
ways in the brain indicates that it may play an impor- 
tant role in CNS function [5,6]. VIP may also regulate 
cerebral energy metabolism [7] and neuronal survival 
[8]. VIP stimulates prolactin secretion from the pituitary 
[9] and catecholamine r lease from the adrenal medulla 
[10]; in the immune system it inhibits mitogen-activated 
proliferation of T cells by inhibiting interleukin-2 pro- 
duction [11]. 
*Corresponding author at MRC Brain Metabolism Unit. Fax: (44) 
(31) 662 0240. 
The nucleotide sequence presented here has been submitted to the 
EMBL/GenBank database under the accession o. Z25885. 
Abbreviations: cAMP, adenosine 3':5'-cyclic monophosphate; cDNA, 
complementary DNA; CGRP, calcitonin gene related peptide; CRF, 
corticotrophin releasing factor; dNTP, deoxynucleotide triphosphate; 
DMEM, Dulbecco's modified Eagle's medium; rGHRH, rat growth 
hormone releasing hormone; GLP, glucagon-like peptide I; mRNA, 
messenger RNA; PACAP, pituitary adenylate cyclase activating pol- 
ypeptide; PCR, polymerase chain reaction; PHI, peptide histidine 
isoleucine; PTH, parathyroid hormone; RNase, ribonuclease; VIP, 
vasoactive intestinal peptide. 
Recently, cDNAs encoding rat [12] and human [13] 
forms ofa VIP receptor have been cloned. This receptor 
is present in lung, liver and intestine, as well as several 
regions of the brain (e.g. cerebral cortex and hippocam- 
pus [5,6]) which contain high densities of specific bind- 
ing sites for VIE Here we report he cloning and expres- 
sion of a second, high affinity, VIP receptor. The recep- 
tor was identified by PCR of rat pituitary cDNA using 
degenerate oligonucleotide primers corresponding to 
the third and seventh transmembrane domains of the 
secretin/calcitonin/parathyroid h rmone family of G 
protein-linked receptors. A full-length cDNA was iso- 
lated from an olfactory bulb cDNA library. We propose 
that the VIP receptor cloned by Ishihara et al. [12] and 
by Sreedharan et al. [13] should be designated the VIPI 
receptor and that the second, high affinity VIP receptor 
identified here be designated the VIP 2 receptor. 
2. EXPERIMENTAL 
2.1. Cloning and sequence analysis of rat VIP 2 receptor 
Methods were essentially as described by Morrow et al. [14]. Ante- 
rior pituitary glands from male rats (Cob Wistar, 250 g) were removed 
and total RNA was isolated by the method of Chomczynski and 
Sacchi [15]. Single-stranded cDNA synthesis and PCR were carried 
out using a commercial kit (Perkin Elmer Cetus). PCR was performed 
using the pair of degenerate 32-mer oligonucleotide primers corre- 
sponding to conserved regions in the third and seventh transmem- 
brane domains of the rat secretin [16], pig calcitonin [17] and opossum 
PTH [18] receptors [14]. Amplified DNA was digested with EcoRI and 
BamHI, ligated into pBluescript (Stratagene) and used to transform 
competent E. coli DS941. Clones with inserts of the expected size were 
sequenced on both strands (Sequenase 2.0 kit; USB). 
One of the clones we identified, RPR4, included a 500 bp insert 
encoding a new member of the receptor family. It was subsequently 
used to screen a commercial cDNA library in the tZapII  vector pre- 
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pared from rat olfactory bulb(Stratagene) in order to obtain a full- 
length cDNA for sequence and functional analysis. Screening and 
plaque purification were performed using standard methods [19]. Pos- 
itive clones were xcised with ExAssist helper phage (Stratagene) and 
re-circularised to generate subclones in the pBluescript SK- ve tor 
prior to sequencing o  both strands. 
2.2. Northern analysis 
Approximately 20pg total RNA from each tissue was separated by 
electrophoresis on denaturing 1.2% agarose/formaldehyde gels,trans- 
ferred to a nitrocellulose membrane (Hybond-C, Amersham) and 
baked for 2 h at 80°C. The membrane was then hybridised with the 
500 bp EcoRI-BamHI fragment from RPR4 that had been labelled 
with [32p]dCTP using random hexanucleotide prim rs (Pharmacia) 
and the Klenow fragment of E. coli DNA polymerase [20]. Hybridisa- 
tion was performed overnight n 50% formamide, 25 mM KPO4, pH 
7.4, 5 x SSC (1 x SSC = 0.15 M NaC1, 0.015 M sodium citrate, pH 
7.0), 5 x Denhardt's solution, 50 pg/ml salmon sperm DNA. The 
membranes were subsequently washed t ice for 20 min in 1% SSC plus 
0.1% SDS at 50°C, then twice more in 0.5% SSC plus 0.1% SDS at 
50°C, and exposed to Fuji RX film. 
2.3. Functional expression of RPR4/6.3 in COS 7 cells' 
For expression in transfected COS 7 cells, the insert from the full- 
length clone (RPR4/6.3) wasexcised as an EeoRI fragment and ligated 
into the EcoRI site of the eukaryotic expression vector, pcDNA-1 
(Invitrogen). Details of transfection a d cAMP assay are described by 
Morrow et al. [14]. COS 7 cells (gift of Dr. Janet Allen) were grown 
in DMEM supplemented with 10% new-born calf serum and100 U/ml 
each of penicillin and streptomycin, in a humidified atmosphere f 
95% air/5% CO2 at a constant temperature of 37°C, and were passaged 
every 34 days. Cells for transfection were trypsinised the day before 
the experiment and plated at a density of approximately 40-50% 
confluency in 75 cm 2 flasks. 
2.4. In situ hybridisation 
Male Wistar Cob rats (200 5  g b.wt.) were anaesthetised with 
pentobarbitone (Sagatal, 40 50mg/kg b.wt., i.p.) and perfused by way 
of the ascending aorta with 20-50 ml of 0.9%(w/v) saline followed by 
approximately 500 ml of an ice-cold solution f 4% paraformaldehyde, 
0.05% glutaraldehyde in 0.1 M borate buffer, pH 9.5. After perfusion, 
the brain and pituitary gland were removed and post-fixed infixative 
without glutaraldehyde, but with the addition of sucrose (30% w/v). 
10 pm sections of tissue were prepared using a sliding microtome and 
mounted onto poly-L-lysine- and gelatine-coated microscope slides. 
For riboprobe synthesis, the pBluescript plasmid containing RPR4 
was digested with EcoRI and 35S- or 33p-labelled antisense strand 
riboprobe synthesised using the T7 RNA polymerase promoter; for 
a control, the plasmid was linearised with BamHI and transcribed with 
T3 RNA polymerase to generate the sense strand probe. The methods 
used for prehybridisation, hybridisation and p st-hybridisation were 
as described by Simmons et al. [21], but with the addition of an extra 
pre-hybridisation step in which, after dehydration in ethanol, sections 
were de-lipidised by immersion in 100% chloroform for 3 min. Hybri- 
disation was for 18-20 h at 50°C with hybridisation solutions contain- 
ing 5 x 107 cpm/ml. After post-hybridisation treatments, slides were 
dip-coated in Ilford K-5 nuclear emulsion (diluted l:l with distilled 
water) and exposed for 5 or 10 weeks (for 33p_ and 3~S-labelled probes, 
respectively) at 4°C after which slides were developed, fixed and 
stained with 1% aqueous pyronin [22]. 
3. RESULTS 
3.1 Isolation and analysis o f  receptor cDNA clones 
With the cloning of the secretin, calcitonin and PTH 
receptors, a new family of G protein-l inked seven trans- 
membrane peptide receptors was identified, which show 
strong homology in their t ransmembrane r gions but 
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Fig. 1. Northern blot analysis of receptor mRNA in rat tissues. 20,ug 
of total RNA from the indicated tissues were probed with the cDNA 
clone, RPR4. A single transcript of approximately 3.5 kb was ob- 
served in each of the tissues shown, but not in COS 7 cells. The 
positions of the 28 S and 18 S ribosomal RNAs are indicated. 
which are quite distinct from the rhodopsin superfamily 
of receptor proteins [23]. To isolate members of this 
family which are involved in CNS and pituitary func- 
tion, we designed oligonucleotide primers correspond- 
ing to the conserved regions of the third and seventh 
transmembrane regions. Amplified fragments were sub- 
cloned and sequenced. One of the cloned PCR frag- 
ments, RPR4, contained a 500 bp insert which encoded 
a new member of this family. Northern blot analysis 
using RPR4 as a hybridisation probe (Fig. l) revealed 
a transcript of approximately 3.5 kb expressed in the 
pituitary and regions of the brain, with the highest levels 
being observed in the olfactory bulb. Accordingly, we 
screened a rat olfactory bulb cDNA library with probes 
for PR4 and, from a total of 400,000 clones, six clones 
were found to hybridize with RPR4. Three of these were 
isolated and characterised by restriction mapping and 
sequencing. All three had sequences corresponding to 
RPR4 but only one cDNA,  RPR4/6.3, containing an 
insert of 3.3 kb, encoded a complete open reading 
frame, encoding a protein of 437 amino acids with a 
predicted molecular mass of 49,519 (Fig. 2). A 22 amino 
acid hydrophobic signal sequence is found at the amino- 
terminal end, with a predicted signal cleavage site be- 
tween Pro 22 and Glu 23 [24]. A hydropathy plot shows 
seven hydrophobic, putative membrane-spanning do-
mains (Fig. 2). Comparison with other members of the 
secretin/calcitonin/PTH receptor family (Fig. 3) re- 
vealed that the predicted protein encoded by RPR4/6.3 
has greatest similarity with the rat VIP I and PACAP 
type I receptors (50% identity). The highest amino acid 
sequence identity is found in the putative transmem- 
brane regions, whereas the sequences of the amino-ter- 
minal extracellular domains and the carboxyl-terminal 
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GCGCTGGGAGGCCCCGAGCTGGCGTTACTGCTGAGGGCGCCAAGGACCGAGGCGGCACTGAGCCCAGG ATG AG  
Met Arg 
TTG CTG GTG CGG GTG AGC AGC ATC CAC CCA GAA TGC CGG TTT CAT CTG GAA ATA CAG GAA 
Leu Leu Val Arg Val Ser Ser Ile His Pro Glu Cys Arg Phe His Leu GIu Ile Gln Glu 
AGC CAA ATG GAG AAT CAC AGA GCT TGC AGC GGT GTC TGG GAC AAC ATC ACA TGC TGG CGC 
Ser Gln Met Glu Asn His Arg Ala Cys Ser Gly Val Trp Asp ASh Ile Thr Cys Trp Arg 
CCC TGC CCC AAA GTG TTC AGC AAT TTC TAC AGC AGA CCA GGA AAC ATA AGC AAA AAC TGC 
Pro CyS Pro Lys Val Phe Set Asn Phe Tyr Set Arg Pro GIy ASh Ile Ser Lys Ash Cys 
GAT TTC ATA GAT GCG TGT GGC TAC AAC GAC CCC GAG GAT GAG AGT AAG ATC ACG TTT TAT 
Asp Phe Ile Asp Ala Cys Gly Tyr ASh Asp Pro Glu Asp Glu Set Lys Ile Thr Phe Tyr 
TAC AGT GTT TCT CTG ATG TCT CTT ACA ACA GGA AGC ATA ATT ATC TGC CTC TTC AOG AAG 
Tyr Ser Val Ser Leu Met Set Leu Thr Thr Gly Set Ile Ile Ile Cys Leu Phe Arg Lys 
AAT CTG TTC CTC TCC TTC ATG CTG AGA GCC ATC TCT GTG CTG GTC AAG GAC AGT GTG CTC 
Asn Leu Phe Leu Ser Phe Met Leu Arg Ala Ile Ser Val Leu Val Lys Asp Set Val Leu 
GAC CAG CCG GGC TCC TGG GTT GGC TGC AAG CTC AGC CTG GTA TTC TTC CAG TAC TGT ATC 
Asp Gln Pro GIy Ser Trp val Gly Cys Lys Leu Ser Leu Val Phe Phe Gln Tyr Cys Ile 
GGT CTC TAC CTG CAC ACC CTC CTG GTA GCC ATC CTT CCT CCC AGC AGG TGT TTC CTG GCC 
Gly Leu Tyr Leu His Thr Leu Leu Val Ala Ile Leu Pro Pro Ser Arg Cys Phe Leu Ala 
GTG TGT ATA GGT GCA TGG ATA GCA ACT CGC CTT TCT TTA GAA GAC ACA GGT TGC TGG GAC 
Val Cys Ile Gly Ala Trp Ile Ala Thr Arg Leu Ser Leu Glu Asp Thr Gly Cys Trp Asp 
ATT CGG ATG CCC ATT CTA ATT TCT ATT GTA GTC AAC TTT GCC CTC TTC ATC AGC ATT GTA 
Ile Arg Met Pro Ile Leu Ile Ser Ile Val Val Asn Phe Ala Leu Phe Ile Ser lie Val 
GAT GTT GGT GGC AAT GAC CAG TCA CAG TAC AAG AGG CTC GCC AAG TCC ACA CTG CTG CTA 
Asp val Gly Gly Asn Asp Gln Ser Gln Tyr Lys Arg Leu Ala Lys Ser Thr Leu Leu Leu 
TTT GCT GCC TTC CCC ATT GGC ATC TCC TCC ACG TAC CAG ATC CTG TTT GAG TTA TGT GTT 
Phe Ala Ala Phe Pro Ile GIy Ile Set Ser Thr Tyr Gln Ile Leu Phe Glu Leu Cys Val 
CTA TAT TGC TTT CTG AAC AGT GAG GTA CAG TGT GAA CTG AAA AGA AGG TGG AGA GGC CTG 
Leu Tyr Cys Phe Leu Asn Ser Glu Val Gln Cys Glu Leu Lys Arg Arg TrD Arg GIy Leu 
CGG CTG CAC AGC TGG TCC ATG TCC CGG AAT GGC TCA GAA AGC GCC CTA CAG ATA CAC CGT 
Arg Leu His Ser Trp Ser Met Ser Arg Asn Gly Ser Glu Set Ala Leu Gln Ile His Arg 
GAG ACC TCA GTC ATT 
Glu Thr Ser Val Ile 
GCG TCG GTG GTG CTG ACC TGC TAC TGC TGG 104 
A]a Set Val Val Leu Thr Cys Tyr Cys Trp 12 
GAG GAG ACA AAA TGT GCA GAG CTG CTA AGC 194 
Glu Glu Thr Lys Cys Ala Glu Leu Leu Ser 42 
CCT GCA GAC ATT GGG GAA ACT GTC ACA GTG 284 
Pro Ala Asp Ile Gly Glu Thr Val Thr Val 72 
ACT AGT GAT GGG TGG TCG GAG ACA TTT CCG 374 
Thr Set Asp Gly Trp Set Glu Thr Phe Pro IG2 
ATT CTG GTG AAG GCC ATT TAT ACC TTG GGC 464 
Ile Leu Val Lys Ala Ile Tyr Thr Leu Gly 132 
CTG CAC TGC ACA AGG AAC TAC ATC CAC CTG 554 
Leu His Cys Thr Arg ASh Tyr Ile His Leu 162 
TAC TCC AGC TCA GGT ACA CTG CGC TGC CAC 644 
Tyr Ser Ser Ser Gly Thr Leu Arg Cys His 192 
ATG GCG AAC TTC TAC TGG CTT CTG GTG GAG 734 
Met Ala Asn Phe Tyr Trp Leu Leu Val Glu 222 
TAC CTT CTT ATT GGA TGG GGT ATC CCC AGT 824 
Tyr Leu Leu Ile Gly Trp Gly Ile Pro Ser 252 
ACG AAC GAC CAC AGC ATC CCC TGG TGG GTC 914 
Thr ASh Asp His Ser Ile Pro Trp Trp Val 282 
AGG ATC TTA CTT CAG AAG CTA ACT TCT CCA 1004 
Arg Ile Leu Leu Gln Lys Leu Thr Set Pro 312 
ATC CCA CTG TTT GGC GTC CAC TAC ATG GTG 1094 
Ile Pro Leu Phe GIy Val His Tyr Met Val 342 
GGT TCC TTC CAG GGC CTG GTG GTC GCA GTT 1184 
Gly Set Phe Gln Gly Leu Val Val Ala Val 372 
TGC CTG ACC CAG CCT GGG AGC CGG GAC TAC 1274 
Cys Leu Thr Gln Pro Gly Ser Arg Asp Tyr 402 
GGC TCC CGT ACC CAG TCC TTC CTG CAG TCA 1364 
Gly Ser Arg Thr Gln Ser Phe Leu Gln Ser 432 
TAGCTGTGTCCCTCATACAGAGCTGACAGTGCTGCTGGGTTTGACATATGTGTTTGCCAGCTTCCTCTGCTTGCCCCAGTGTCTGGTGCCTTATTGGGT 1478 
437 
CAGCCCTGGTCCTTAACTCGATTGTAACTTGATTGAAACACCAGTTATTGTTGACAGACTCTAGCCTTTAAGCCATCCTCTTCATAATATGGCACAGCCATATTCTACTTTCAAAGAGA 1597 
GCAAGGAAACCAGGTGGCCCTGAACATCAAAACTGGGTTCTAGAACGTCCGAAAAAAAACAAGGAGGAAGATTCCAGTTTCTCCACTGCCTCCTGTCAGGGAGAACCACGTCCAGAACC 1716 
AGCTGAGCATCACCACCCTGTGGCCCAGCGCATGCCTATGGTTGTCTCTGACATTCCTCTCAATCTATGGCATACCAGGGAAAGTGGATGAAAGCAACCTTCTCATCCTACAAGCTTCC 1835 
TGGTGCCCCCGGCCTTGAGTTCTGTCCTGTGGACTACATCTGGACAGCCACACCCTTGCCATTCCCTGGACCATCTGGTAGTGACCAAAGATAAGTCAGGGAGGATATTCATGGTTCAG 1954 
CGGCCAAGCCAGGAACTCATCTCCTCCCAGGGCACTTAGCATCTGCTGCTTCCTACAAGTGGTGAGCAGCCCTGGATCCCAGGCCGGCTGCTGGCATGAAGGCCCTCATTCATGACTTG 2073 
TCCATTCAGCCCAAGGTTGTTCTCTAGCTGGTAGAAAAACTTCGATTTTTATT 2126 
b 
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Fig. 2. Sequence of the rat VIP  2 receptor cDNA and polypeptide. (a) DNA sequence and predicted amino acid sequence of rat cDNA clone 
RPR4/6.3. (b) Hydropathy plot of the rat VIP2 receptor protein. The strongly hydrophobic region at the N-terminus corresponds to the signal 
sequence. A further seven hydrophobic putative membrane-spanning regions are numbered 1 7. The numbers on the horizontal scale refer to amino 
acid positions. 
cytoplasmic ends are highly divergent. Certain specific 
amino acid residues found to be conserved in other 
members of  this family are also present in the protein 
encoded by RPR4/6.3. For instance, there are eight con- 
served cysteine residues in the extracellular domains of  
the VIP~, secretin, GHRH and PACAP type I receptors 
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** ** , • 
MRASVVLTCYCWLLVRV . . . . . . . . . . . .  SS I H PECRFHLE IQEEETKCAELL  . . . . . .  S SQMENHRAC SGV~N ~TCWRPADIGETVTVPCPKVFSNFY SRp . . . . . . . . . . . . . . . . . . . . . . .  GNISF~NCTSDG-W . . . .  SETFP~ 
MR P PS PpHVRWLCVLACALACALR PAGSQAAS PQBECEYLQL I E ~QRQQCLEE . . . . . . .  AQLENETTGC SKMWDNLTCWPTTpRGQAVVLDC pL I FQLFA P I HG . . . . . . . . . . . . . . . . . . . . . .  YN ISRSCTEEG-W . . . .  SQLEPG 
HARVLQLS LTALLL~V . . . . . . . . . . .  A IAMHSDC I F- - - - F~EQAMCLE~ I QRANDLMGLNESS PGCPGMWDN~TCWK PAQVG£~fVLVSC PE~rFE I FNPDQVWHTETI  GDSGFADSNS LE  I TDMGWGRNCTEI3G -W- - - -SEPFP-  
MLSTMR PRLS LLLLRLLL -  - LTKAAHTVGVP PRLCDVRRVLLEERAHCLQQLSKEKKGALGpETASGCEGLWDNM$CWPSSAPARTVEVQC PKFL[ J~LSNKN . . . . . . . . . . . . . . . . . . . . . . .  GSLFRNCTQDG -W . . . .  SETF  PR 
MDSLLWATWVLC LLNLWG . . . . . . .  VALGHLHLECDF ITQLRDDELACLQA . . . . . .  AEGTNNSSMGC PG~LLCWP PTGSGQWVSL PC PEFFSHFGSDP . . . . . . . . . . . . . . . . . . . . . . .  GAVKRDCTITG-W . . . .  SDPFP-  
MAVT PS 5LRLALLLLGAVG - -. RAG pR pQGATVSLSETVQKWREYRHQCQRFLT  . . . .  EA  PLLATGLFCNRTFDDYACWPDC P PGSFVNVSC pWYLPWAS SVLQ . . . . . . . . . . . . . . . . . . . . . .  GKVYRFCTAEG IWLHKDNSSLPW 
MLLTQLHC PYLLLLLVVLSC . . . . .  L PKA P SAQ\rMDFLF EKWKLY S DQC H HNL . . . . .  SLLP  PPTESVCNRTFDKV SCWpDTpPNTTANISC pWYL PWYHKVQH . . . . . . . . . . . . . . . . . . . . . .  RLVFK RCG PDGQWV - RGPRGQ SW 
o* * * * *** *o *. ** * . ° * , *  * ** ** 
DFIDACGYNDPE . . . .  DESK I TFy  I LVKA I YTLGYSVSLMS L~'IX3S I I I CLFRKLHCTENY I HLHLFLSFMLRAI  S VLVKDSVL - ~ ~ Y$S SGTLR - - CHD÷ Q PG- S WVGCKLS LVFFQYC :MANFYWLLVEGLYLH~LL  -VA I L p pS RC F 
py H I ACGLNDBA$ SLDEQQQTKFY NTVKTGY T ~Gy SLS  LASLLVAMA I LSLFRKLRCTRNY I H~L FMSF I LRATAVF IKDMAL - - - FNSGEIDH-  -CSE-AS- -  - - VGCKAAVVFF  QYCV~ FWLLVEGLy  LYTLLAVS FFS  ERKy F 
HYFDACGFDDYEPE-  SGDQDY - yyLSVKALYTVGYSTSLATLTTAMVI  LCRFRKLHCTRNF IHHNLFVSFMLRA I SVF  IKDWI  L-  - - YAEQDS$ H ~ - CFV-  ST-  - - - VECKAVHVFFHYCWSNYFWLF I EGLYLFTLLVETFF  PERRYF  
PDL-  ACGVNINNS-  - FNERRHAYLLKLKVHYTVGYSS SLAMLLVALS ILC SFRRLHCTRNY I H~LFVSF  ILRALSNF IKDAVL - - - FSSDDVTY-  - CDA-HK . . . .  VGCKLVHIFFQYC IMANYAWLLVEGLYLHTLLA I SFFSER/<YL 
PZPVACPVPLELL  . . . .  TEEKS•FSTVKIIYT•x3HSISIVALCVA•AILvALRRLHC•RNYIHTQLFATFILKASAV•LKDAAV---FQ•DSTDH• -CSM- ST  . . . .  I LCKVSVAVSH FATM~SWLLAEAVY LSCLLASTS PRSKPAF 
RDLS E~EESKQGE- - -  RN$ PEEQLLS L¥ I I YTVGYALSFSALV IASA I LVS  FRHLHCTKNY I HLNLFASF I  L RALSVF  I K DAALK~MYSTAAQQHQWDGL-  LSYQDSLGCRLVFLLMQYCVAANYYWLLVEGVX 5YTLLAFSVFS E QRI  F 
R DASQCQMDDDE I E -VQKGVA~MYS S YQVMYTVGy S L S LGAL  L LALV I L LG LP~KL H C TRNY I HGNLFASFVLKAGSVLVI  DWLLKTRYSQK I GDDLSVSVWLSDGAVAGC RVATVIMQYG I I ANYCWLLVEGVYLYSLLS  I TTFSEKSFF  
LAY  LL  IGWGI  PSVC I GAWIATR LSLEDTGCWIY~NDHS I pWWVI  RM P I L I S IVVNFALF  I S I VR  I LLQK LTS  PDVC43NDQSQYK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ELAKSTLLL  I PDFGVHYMVFAAFP IG I 
WGY I L ~GWGV PSVF  IT IWTVV~ I YFEDFGCWI~ I I NSSLWWI  I KA  P I LLS  I LVNFVLF  I C I I R I LVQKLRPPDIGKNDSS PY S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  RLAKSTLLL  I PLF~ I HYVMFAFFPDNF 
YWYTI  ~CWGTPTVC~AVLRLYFDDAGCWDMNDSTALWWVl  KGPVVGS IMV~F IO I I I I LVQKLQSPDMCGNESS IYPSCVQKCYCKPQRAQQH SCKMS ELST  ITL . . . . . . . . . . . .  RLARSTLLL  I PLF~ IHYTVFAFS PENV 
QAF 'VLLGWGS~A I FVALWAITRH FLEI~FfGCWD ~NANASV~ I RG~VILS I  L~NFIFF  IN ~ LR ILM~LRTQETKGSETNHYK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  RLAKSTLLL~ PLFG [ MY IVFAFSPEDA 
WWLVLAGWGLPVLCTGTWVGCKLAFEDTACWDLDDS$ p YWWI  IKG P I VLSVGVNFGLFLN I I C I LLRKLGPAQGGLHTRAQYNYLL  PWSC PLPQVPRERTDLG PS S HE I TVQE$OTRNCQLPWRLSKSTLLL  I P LFO I H Y I I F NFLPDSA 
KLYLS  IGWGVPLLFV I  PWG IVKYLYEDEGCWTRNSNMNYWL I I RL  P I LFA  IGg~NFLVF I RV  I C IV IAKLKANLMCKTDIKC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  RLAKSTLTL I  PLLGTHEV~FAFVMDEH 
SLYLC IGWGS PLLFV I pWVVV~CLFENVQCWTSNDNMGFWW I LR  I pVLLA I L INFF  I FVR I  I HLLVA~LRAHQMHYADYKF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  RLARSTLTL  I PLLGVHEVV~AFVTDER 
• ****  ** **,• * ** * * 
SST-  - - - yQ I LFELCVGS FQGLWAVLYC FLNS EVQCELKRRWRGLCL . . . . . . .  TQPGSRDY RLHSWSMSRNGSESALQ-  - IHRGSR-  - - -TQSFLQSETSV[  
KAQ . . . .  VKMVFE LWG S FQGFVVA I Ly  C F LNG EVQAELRRKWRRWH L . . . . . .  QGVLGWSSKSQH PWGGENGATCSTQVSMLTRVS P . . . .  SARRSSSFQAEVSLV 
SKR . . . .  ~ RLV]?E LGLG S FQGFVVAVLy  C FL~ EVQAE I K RKWR SWKV . . . . . .  NRyF ' fMDFKHRH pSLASSGVNGGTQLS ILSKS SS . . . .  QLRMSSL  PADNLAT 
HE . . . . .  VQ 5F  FE  LA  LGS F QG LWAVLy  C FLNGEVQ LE'VQKKWR QWH L . . . . . .  QEFPLRPVAFNNSFSNATNGPTHS . . . . .  TKAST . . . .  EQSRSIPRASI  
GLG . . . .  I RL  P LBLGLGS FQGFVVAVL¥C FLNQEVRTE ~ SRKW . . . . . . . . . . . . . .  YGNDPELLPA~RTCTE . . . . . . . . . . .  W~p . . . .  PRS RVKVLTSEC 
ARGTSR FV~ L FTELSFTS FQ~FMVAVLy  C F ~ Q M E  F RKSWERWR L . . . . . .  ERLN IQRDSSMKPLKC PTSSVSSG . . . . .  ATVGS . . . .  SVYAATCQNSCS 
AQ~TL~sTKLFFDLFFSSFQGLLVAVLYC FLNKEVQAELLRRWREWQECKALQEEKMAS S HGSHMAPAGTCHGDPCEKLQLMSAOSSSGTGC E BSAKTSLASSL  pRLADS PT 
Fig. 3. Alignment of the rat VIP~, VIP2, PACAP, secretin, GHRH, GLP, and glucagon receptors. Amino acids identical in all seven receptors 
are indicated with an asterisk. Putative transmembrane regions are indicated by lines above the sequence. 
(Fig. 3), which are also present in the receptor encoded 
by RPR4/6.3. These probably maintain the tertiary 
structure of the extracellular ligand-binding domain. 
Potential sites of N-linked glycosylation are found in 
the amino-terminal extracellular domain at residues 57, 
87 and 91 (Fig. 2). 
3.2. Functional expression of RPR4/6.3 in transfected 
COS 7 cells' 
All members of the secretin/calcitonin/PTH receptor 
family which have been identified to date are associated 
with activation of adenylyl cyclase. In order to identify 
the ligands which activate this novel receptor, the EcoRI 
fragment of the RPR4/6.3 cDNA was cloned into the 
mammalian cell expression vector, pcDNA-1 (Invitro- 
gen), and used to transfect COS 7 cells. Transfected cells 
were challenged with several potential igands to deter- 
mine their ability to increase intracellular cAMP levels, 
as measured by radioimmunoassay. The peptide 
hormones, VIP, PHI, helodermin, rGHRH, PACAP-38 
and PACAP-27, evoked a marked dose-dependent ele- 
vation of cAMP levels, while CRF, CGRP, secretin and 
glucagon had negligible effects (Fig. 4). PHI, VIP and 
PACAP-38 failed to elevate cAMP levels in COS 7 cells 
transfected with the 5HT1A receptor (data not shown). 
The ECs0 for cAMP accumulation was approximately 
0.18 nM for PACAP-38, 0.43 nM for PACAP-27, 0.25 
nM for helodermin, 0.17 nM for VIP and 2.14 nM for 
PHI. The maximal stimulation of cAMP accumulation 
by rGHRH (400nM) was only 60% of that found for 
VIP (data not shown). We therefore conclude that the 
order of potency of these ligands is V IP -  PACAP- 
27 - PACAP-38 ~ helodermin > PHI > > rGHRH, and 
that accordingly, RPR4/6.3 encodes a VIP receptor. 
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Fig. 4. Measurement of cAMP production in COS 7 cells transfected 
with RPR4/6.3. (a) Cells transfected with RPR4/6.3 were stimulated 
with the ligands indicated, each at a concentration of 100M. Values 
of cAMP are expressed (mean + S.E.M,, n = 3) as a percentage of the 
stimulation evoked by 100 nM VIP. (b) cAMP accumulation in COS 
7 cells in response to VIP (A), PACAP 38 (©), PACAP 27 ([]), helod- 
ermin (zs), and PHI (e). The values represent the mean (n = 3). The 
basal cAMP level was measured at 0.8 +_ 0.15 pmol/well. 
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Fig. 5. In situ hybridisation of VIP2 receptor mRNA in rat brain. Dark-field photomicrographs of VIPz receptor mRNA expression i  suprachi- 
asmatic nucleus ( pper left), hippocampus ( pper right), dorsomedial thalamic nucleus (lower left) and ventromedial th amic nucleus (lower ight). 
Large white arrow indicates the CA1-3 subfields of the hippocampus; CI, internal capsule; OC, optic chiasma; DG, granule cells of the dentate 
gyrus; SCN, suprachiasmatic nu leus; VE, ventromedial nucleus of the thalamus; 3V, third ventricle. Bar = 100 ,urn. 
3.3. Distribution of VIP2 mRNA as assessed by in situ 
hybridisation 
In situ hybridisation showed that VIP2 receptor 
mRNA was present chiefly in the suprachiasmatic nu- 
cleus, paraventricular nucleus of the thalamus, medio- 
dorsal and ventral thalamus, in cells of the CA1 CA3 
subfields of the hippocampus and in the dentate gyrus 
(Fig. 5). In the olfactory bulb, receptor mRNA was 
present in all layers, albeit at lower levels, with the 
exception of the external plexiform layer. Some labelled 
cells were present in the paraventricular nucleus of the 
hypothalamus and supraoptic nucleus. Pituitary cells 
also appeared to contain low levels of receptor mRNA. 
Labelled cells were not found in the cerebral cortex or 
cerebellum. No labelled cells were present in control 
sections probed with the labelled sense strand ribo- 
probe. 
4. DISCUSSION 
This is the first report of the existence in rat of a novel 
VIP2 receptor. The receptor belongs to a new sub-class of 
G protein-linked peptide receptors which includes re- 
ceptors for calcitonin, PTH, glucagon, secretin, GHRH 
and PACAP. Northern blot analysis and in situ hybri- 
disation histochemistry indicated that the receptor had a 
distribution in brain distinct from that of other members 
of this receptor family, with high levels in the olfactory 
bulb, thalamus, hippocampus and suprachiasmatic nuclei. 
A number of lines of evidence suggest that VIP recep- 
tors in the brain and periphery may be heterogeneous 
[25]. Cross-linking studies have been used to identify 
V1P-binding proteins in tissues with molecular weights 
ranging from 46,000 to 73,000 Da, depending on the 
tissue and species [26]. Studies with peptide analogs al o 
suggest he existence of more than one pharmacologi- 
cally distinct class of VIP receptor [27-31]. At least two 
types of membrane r ceptor capable of specific binding 
of VIP have been distinguished. One of these, also 
known as the PACAP Type II receptor [32], recognises 
VIE PACAP-27 and PACAP-38 with very similar affin- 
ities. This receptor is present in a variety of peripheral 
tissues, including rat liver, rat lung, mouse splenocytes 
and human small intestinal epithelium [32-36], as well 
as certain areas of the CNS, such as the cortex, hypo- 
thalamus, hippocampus and cerebellum [37]. A second 
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VIP receptor, for which helodermin is the most potent 
ligand, has been identified in certain human cell lines, 
including the lymphoblastic ell line, SUP-Tl[38, 39], 
the THP-1 monocyte/macrophage c ll line [40], and 
NCI-H345 lung carcinoma cells [41]. 
Hill et al. [42] have distinguished two subtypes (or 
different functional states of a single subtype) of VIP 
receptor which differ in their sensitivity to GTP analogs. 
In some brain regions, guanylyl-imidodiphosphate 
(GMPPNP) substantially inhibited VIP binding. In 
other regions, VIP binding was insensitive to 
GMPPNP. Both types of receptor are present in the 
mouse embryo [43], where they are differentially regu- 
lated by treatment with a VIP antagonist. Several of the 
tissues which contain GTP-insensitive VIP receptors 
(olfactory bulb, pituitary and ventral thalamic nuclei) 
are regions in which the VIP 2 receptor is present. 
The present study provides the first evidence for VIP 
receptor heterogeneity at the molecular level. VIP1 and 
VIP2 receptors have distinct distributions in the CNS, 
with high levels of VIPI receptor mRNA in cortex, hip- 
pocampus, hypothalamus and cerebellum [12] and VIP 2 
receptors in hippocampus, thalamus and suprachias- 
matic nucleus. The distribution of VIP-binding sites in 
the CNS, determined by autoradiography, is consistent 
with the combined distributions of the VIP~ and VIP2 
receptor mRNAs. 
In conclusion, we have identified a novel VIP recep- 
tor which is distinct in sequence and distribution from 
the VIPI receptor. The characterisation of the VIP2 re- 
ceptor will permit the identification of selective 
VIP2agonists and antagonists and will lead to 
a better understanding of the physiological role of VIP 
in the central nervous system and in the periphery. 
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